"Siemens' product offerings and leadership in the radiotherapy market are world-class. By combining Calypso's technology platform with cutting edge Siemens products, we will be well-positioned to develop advanced radiation therapy technologies," said Eric R. Meier, president and chief executive officer of Calypso Medical. "This agreement will provide the framework for joint development of real-time multi-leaf collimater (MLC) tracking, a future capability* which will significantly enhance the delivery of radiation to difficult-to-treat areas such as the pancreas and lung, as well as for our current prostate cancer patients."
"MLC tracking guided by the Calypso System can maximize treatment efficiency while ensuring pinpoint delivery of radiation to the tumor, even in the presence of significant tumor motion," said Uwe Oelfke, MCCPM, FInstP, professor of medical radiation physics at the German Cancer Research Center (DKFZ).
"We are very pleased with the MDA with Calypso Medical as this will allow us to more rapidly develop new approaches for the delivery of radiation therapy," said Holger Schmidt, chief executive officer of Oncology Care Systems for Siemens Healthcare. "We believe our technologies complement one another ideally and once fully integrated may lead to improved outcomes and a better quality-of-life for all cancer patients."
"We use the Calypso System to ensure the precise delivery of radiation to our prostate patients, even with reduced margins. As both a Siemens and Calypso user, we are very encouraged by this new development agreement with Siemens," said Charles Enke, M.D., chairman of the department of radiation oncology at the University of Nebraska Medical Center.
((Comments on this story may be sent to health@closeupmedia.com))

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index